Bibliography for: "Impact of efalizumab on psoriasis-specific patient-reported outcomes: results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis"

Alan Menter "Impact of efalizumab on psoriasis-specific patient-reported outcomes: results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis". Journal of Drugs in Dermatology. FindArticles.com. 16 Dec, 2009. http://findarticles.com/p/articles/mi_m0PDG/is_1_3/ai_113650070/

Journal of Drugs in Dermatology

View more issues:

Articles in Jan-Feb, 2004 issue of Journal of Drugs in Dermatology

• Picaridin: a new insect repellent
  by Noah Scheinfeld
• Effects of therapy on quality of life in melanoma patients receiving different treatments
• Combination therapy of interleukin-12 and interleukin-2 to treat advanced cancer
• The sun as an immunosuppressant: why sun-induced skin lesions make excellent targets for immune response modifiers
• The nuances of dealing with cosmetic patients
  by Wendy Lewis
• Recombinant alpha-1-antitrypsin gel studied for the treatment of atopic dermatitis
• Determine the efficacy of topical tretinoin cream for the prevention of nonmelanoma skin cancer
• Photorejuvenation with Intense Pulsed Light: results of a multi-center study
  by Neil S. Sadick
• Primary cutaneous B-cell lymphoma in a 74-year-old Caucasian male
  by Boaz Kurtis
• Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia
  by M.D. Davis
• Etanercept to treat wegener's granulomatosis
• ALA-PDT and blue light therapy for hidradenitis suppurativa
  by Michael H. Gold
• Onychomycosis: classification and diagnosis
  by Aditya K. Gupta
• Genetic testing for inherited predisposition to melanoma: has the time come?
  by Mary C. Fraser
• A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome
  by G. Hu
• Depsipeptide to treat T-cell lymphomas
• Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage
  by David K. Avram
• A letter from the Editor-in-Chief
  by Perry Robins
• Dermatologic look- or sound-alike medications
  by Loretta Gremillion
• Riquent reduces lupus antibodies believed to cause renal disease
• Gp100 and MART-1 peptide vaccine for metastatic ocular melanoma
• Randomized double-blind study of ONTAK® in cutaneous T-cell lymphoma patients
• Impact of efalizumab on psoriasis-specific patient-reported outcomes: results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis
  by Alan Menter
• Venous thrombosis occurring after initiation of thalidomide for the treatment of cicatricial pemphigoid
  by Eric Howell
• HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris
  by L. Skov
• Evaluation, treatment, and follow-up of patients with lyme disease
• Large surface photodynamic therapy with aminolevulinic acid: treatment of actinic keratoses and beyond
  by Robert Bissonette
• And the beat goes on: formulary restriction, generic substitution, prior authorization, drug utilization, and now therapeutic interchange
  by Craig G. Burkhart
• Imiquimod as a possible treatment for keratoacanthoma
  by Neal Bhatia
• Dalbavancin enters Phase III clinical trial in the treatment of skin infections
• Photodynamic therapy in treating patients with lymphoma or chronic lymphocytic leukemia
• Phase II trial of allovectin-7® for metastatic melanoma
• Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy?
  by Joseph Jorizzo
• Cutaneous vasculitis secondary to ramipril
  by S. Gupta
• Abbott expands trial of its drug Humira in the treatment of psoriatic arthritis
• Photodynamic therapy in dermatology: history and horizons
  by Amy Forman Taub
• Provectus advances its development of Xantryl for the treatment of psoriasis
• Tyrosinase-related protein vaccination for metastatic melanoma
• Open label study of ONTAK® in previously treated cutaneous T-cell lymphoma patients
• Diphenhydramine gargling may slow the healing of oral lesions of pemphigus vulgaris
• Localized heat induced urticaria: report of a case
  by Matthew Darling
• ILX-651 enters Phase II studies in patients with metastatic melanoma
• Thalidomide to treat oral lesions in HIV-infected patients
• Previously unpublished case reports and case studies are eligible for this open-ended contest
• Redefining clinical response in psoriasis: targeting the pathological basis of disease
  by Jean-Paul Ortonne
• Generalized pustular psoriasis following with-drawal of efalizumab
  by Minh-Ly N. Gaylor
• Peptimmune begins Phase I trial for pemphigus vulgaris
• PS-341 alone and PS-341 plus EPOCH chemotherapy to treat non-hodgkin's lymphoma
• Photodynamic therapy comes of age
  by Mitchel P. Goldman